GlassScriptPhysician profile
Jonathan M Mcareavey
NPI 1730147125
$5,412.37
in general payments reported to CMS, 2019-2025
35 companies · $662 in 2025
The $662 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $424 · 2021: $1,140 · 2022: $1,007 · 2023: $967 · 2024: $881 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $602.60 | 2022-2025 | |
| Abbvie INC. | $599.67 | 2021-2025 | |
| Lilly USA, LLC | $592.16 | 2021-2025 | Mounjaro, Zepbound, Basaglar |
| Grifols USA, LLC | $460.54 | 2020-2024 | Prolastin-C Liquid |
| Astellas Pharma US INC | $385.86 | 2020-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $346.46 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $296.18 | 2019-2025 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $289.42 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $279.50 | 2019-2024 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $267.36 | 2020-2025 | Injectafer |
| Dexcom, INC. | $191.59 | 2021-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.52 | 2019-2023 | Ofev, Jardiance |
| Abbott Laboratories | $126.13 | 2021-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $118.36 | 2022 | |
| Sunovion Pharmaceuticals INC. | $74.08 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $72.36 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $69.50 | 2019-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Novartis Pharmaceuticals Corporation | $68.31 | 2021-2024 | |
| Exact Sciences Corporation | $61.17 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $53.46 | 2021-2025 | |
| Amarin Pharma, INC. | $49.33 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.10 | 2021 | |
| Collegium Pharmaceutical, INC. | $31.21 | 2025 | Jornay Pm |
| Genentech USA, INC. | $30.27 | 2020 | |
| Abiomed | $25.68 | 2024 | Impella |
| Organon LLC | $24.92 | 2023 | Nexplanon |
| Medtronic, INC. | $24.23 | 2024 | Minimed 780g |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.99 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $15.74 | 2024 | Arexvy, Bexsero, Shingrix |
| Sanofi-Aventis U.S. LLC | $15.59 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.81 | 2024 | Opsumit, Uptravi |
| Boston Scientific Corporation | $13.73 | 2024 | Watchman Flx |
| Biohaven Pharmaceuticals, INC. | $12.52 | 2021 | |
| Allergan, INC. | $11.09 | 2021 | |
| Electromed, INC. | $1.93 | 2024 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mcareavey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.